Sydney, January 21, 2026, 17:28 AEDT — The market has closed.
- Wesfarmers shares slipped 2.65%, ending the session at A$81.12.
- Priceline’s recent update on Infinity pharmacies shines a spotlight on Wesfarmers Health’s exposure.
- The company is set to release its half-year results on Feb. 19.
Wesfarmers Ltd (WES.AX) saw its shares drop 2.65% on Wednesday, closing at A$81.12. This decline leaves the retail giant on the defensive as it heads into the next trading day. 1
The market is closed for now, but the stock still has two near-term catalysts: a half-year update due Feb. 19 and ongoing fallout from management issues at a major Priceline Pharmacy franchise group.
Wesfarmers announced in an ASX filing that it will release its 2026 half-year results on Thursday, Feb. 19, with an analyst briefing scheduled for 10:00 a.m. AWST (1:00 p.m. AEDT).
That date is crucial—it marks the next official update on how major retail chains are faring during a pivotal trading stretch, and reveals if cost pressures are fading or holding firm.
Priceline Pharmacy’s chief customer officer, Richard Pearson, pushed back against what he described as “inaccurate” media coverage around Infinity’s move into administration. “Our decision to appoint receivers and administrators was not taken lightly,” he said, adding that Priceline had “no option but to draw a line in the sand.” 2
KPMG, named receiver of companies running pharmacies within the Infinity group, said the appointment took effect on Dec. 17, 2025. The firm listed George Georges, David Hardy, Gayle Dickerson, and Will Colwell as the appointed receivers. KPMG also noted that Teneo partners were brought in as voluntary administrators for these entities, a type of external management used during insolvency. 3
Wesfarmers investors will find the issue tied to a business the company has been expanding since acquiring Australian Pharmaceutical Industries in 2022. The Health division, Wesfarmers says, encompasses Priceline Pharmacy, which runs through franchise partnerships at 419 community pharmacies, plus wholesale distribution. 4
Timing remains the key risk. Even if sales at impacted pharmacies remain steady, investors will scrutinize any ripple effects on wholesale volumes, receivables, and provisioning — plus whether the group faces more cleanup than current market valuations suggest.
Beyond company updates, Thursday’s ABS labour force report for December, due at 11:30 a.m. AEDT, stands as the next key local macro event. This data could sway rate expectations and impact sentiment around consumer stocks. 5
Wesfarmers is eyeing Feb. 19 for its half-year results and briefing. That’s when management is expected to provide concrete figures on trading conditions and any effects tied to its pharmacy business.
